<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575428</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00103788</org_study_id>
    <nct_id>NCT04575428</nct_id>
  </id_info>
  <brief_title>Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)</brief_title>
  <official_title>Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Splanchnic vasoconstriction may contribute to decompensation of chronic heart failure (HF)&#xD;
      via volume redistribution from the splanchnic vascular bed to the central compartment. This&#xD;
      is a sympathetically mediated reflex and can be interrupted through a splanchnic nerve block&#xD;
      (SNB). We hypothesize that interruption of the efferent/afferent innervation of the&#xD;
      splanchnic vasculature will decrease cardiac congestion in patients presenting with HF. Based&#xD;
      on preliminary safety and efficacy data in acute and chronic heart failure patients with&#xD;
      temporary (&lt;24 h) SNB. Now we will apply a prolonged SNB in chronic heart failure patients&#xD;
      using a long acting agent. We will test the effects of SNB on long term exercise capacitance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Activation of splanchnic nerves results in vasoconstriction and reduces splanchnic&#xD;
      capacitance, therefore recruiting blood volume into the central circulation. In heart&#xD;
      failure, a reduced splanchnic vascular capacitance could be the mechanism underlying symptoms&#xD;
      of exercise intolerance and could predispose to rapid decompensation with external fluid&#xD;
      intake or retention. A compromised vascular reservoir is likely unable to buffer shifts of&#xD;
      fluid and actively contributes to the acute or chronic expulsion of fluid from the splanchnic&#xD;
      vascular compartment to the central thoracic compartment. The redistribution of blood volume&#xD;
      into the central circulation may lead to a sudden rise in pulmonary and left-sided cardiac&#xD;
      pressures in HF. This makes the splanchnic vascular compartment an attractive target in heart&#xD;
      failure. Our preliminary proof-of-concept work in patients with acute decompensated and&#xD;
      chronic heart failure showed promise for the concept of splanchnic nerve modulation in heart&#xD;
      failure. In a series of two small first-in-human studies for acute decompensated heart&#xD;
      failure (N=13) (NCT02669407) and chronic heart failure (N=17) (NCT03453151), we found that a&#xD;
      splanchnic nerve block (SNB) with lidocaine (90 min duration of action) and ropivacaine (24&#xD;
      hours duration of action) acutely reduced resting and exercise-induced intra-cardiac filling&#xD;
      pressures, associated with improved patient symptoms and functional capacity.&#xD;
&#xD;
      The present study will be a prospective open-label pilot study to help establish feasibility,&#xD;
      safety and enable dose finding for botulinumtoxin. Following a baseline invasive (right heart&#xD;
      catheterization) cardiopulmonary exercise testing (CPX) patients will undergo unilateral&#xD;
      celiac plexus block, followed by repeat hemodynamic testing. Functional testing at baseline&#xD;
      and follow up will be supplemented by measures of blood volume and autonomic tone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak exercise wedge pressure</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak pulmonary arterial pressure</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of nerve block related complications</measure>
    <time_frame>8 weeks</time_frame>
    <description>orthostasis, gastrointestinal symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak oxygen uptake</measure>
    <time_frame>4 weeks</time_frame>
    <description>Peak VO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting wedge pressure</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting central venous pressure</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting pulmonary arterial pressure</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>4 weeks</time_frame>
    <description>dyspnea scales</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Splanchnic nerve block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Splanchnic nerve block</intervention_name>
    <description>Percutaneous splanchnic nerve block</description>
    <arm_group_label>Splanchnic nerve block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Followed at DUMC for known or suspected diagnosis of HF (NYHA stage 2-4, Class C-D),&#xD;
             including patients on inotropic medication&#xD;
&#xD;
          -  Systolic blood pressure (SBP) &gt; 100 mmHg&#xD;
&#xD;
          -  History of HF hospitalization or ER visit or iv diuretic use in last 12 months.&#xD;
&#xD;
          -  Patients will be included regardless of left ventricular ejection fraction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anticoagulation at the time the procedure or in case of recent warfarin use an INR&#xD;
             &gt;1.4. Anticoagulation includes: warfarin, or novel oral anticoagulants like&#xD;
             dabigatran, rivaroxaban, apixaban, endoxaban or full dose intravenous heparin products&#xD;
             or bivalirudin and fondaparinux). Antiplatelet agents besides aspirin such as&#xD;
             ticagrelor, prasugrel, Plavix are also considered to be a contraindication if used at&#xD;
             time point of procedure.&#xD;
&#xD;
          -  Immunosuppressive medications for solid organ transplant&#xD;
&#xD;
          -  Acute MI (STEMI or Type I NSTEMI) within 7 days?&#xD;
&#xD;
          -  Evidence of progressive cardiogenic shock within 48 hours&#xD;
&#xD;
          -  Restrictive cardiomyopathy&#xD;
&#xD;
          -  Constrictive pericarditis&#xD;
&#xD;
          -  Pericardial effusion with evidence of tamponade&#xD;
&#xD;
          -  Severe valvular stenosis requiring intervention&#xD;
&#xD;
          -  Known history of an increased bleeding risk&#xD;
&#xD;
          -  Thrombocytopenia (&lt; 50,000)&#xD;
&#xD;
          -  End-stage renal disease CKD stage 5 due to primary renal pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marat Fudim, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Universtiy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marat Fudim, MD, MHS</last_name>
    <phone>9196848111</phone>
    <email>marat.fudim@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manesh Patel, MD</last_name>
    <phone>9196688917</phone>
    <email>manesh.patel@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manesh Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure, exercise, splanchnic nerve block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

